Lilly’s Orforglipron Tops Novo’s Semaglutide In Diabetes Trial

 
• By Joseph Haas
  
This is a picture of the Lilly building in San Diego
Lilly's oral GLP-1 tops semaglutide in a head-to-head diabetes study (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D